reports
EQS-News: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Establishes an At-the-Market (ATM) Program on Nasdaq 19.11.2024 / 22:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in p...
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allowing the Company to issue and sell, i...
EQS-News: Abivax presents third quarter 2024 key financial information
EQS-News: ABIVAX / Key word(s): Quarter Results Abivax presents third quarter 2024 key financial information 14.11.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory respon...
Abivax presents third quarter 2024 key financial information
Abivax presents third quarter 2024 key financial information Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. Abivax provided the...
EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appo...
EQS-News: ABIVAX / Key word(s): Personnel Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax 13.11.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural ...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as B...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Bo...
EQS-News: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their ...
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation 07.10.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), ...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Priz...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response ...
Abivax: 1 director
A director at Abivax sold 117,630 shares at 9.097EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
EQS-News: Abivax Announces First Patient Enrolled in ENHANCE-CD, the P...
EQS-News: ABIVAX / Key word(s): Study Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease 03.10.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harne...
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Tr...
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first p...
EQS-News: Abivax Reports Positive Interim Efficacy and Safety Analysis...
EQS-News: ABIVAX / Key word(s): Study/Study results Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance 03.10.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated dose of 25 mg of obefazimo...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-D...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated dose of 25 mg of obefazimod once daily demonstrated maintenance of clinical remission at weeks 48 and 96Efficacy and safety demonstrated out to six years of treatment The treatment was well-tole...
EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerati...
EQS-News: ABIVAX / Key word(s): Study results/Conference Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 26.09.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely a...
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis...
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label mai...
EQS-News: Abivax Provides Update on Ulcerative Colitis Combination The...
EQS-News: ABIVAX / Key word(s): Study Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model 25.09.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax is actively conducti...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy ...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024.Pre-clinical evaluation of ob...
- Stephane Beyazian
- Stephane Beyazian
- Damien Choplain
- Martial Descoutures
Abivax : Financial visibility out to Q4 2025 confirmed
>No surprises in the first-half results - The company reported an operating loss of € 80.0m for H1 2024 vs a loss of € 37.3m last year. The difference is due to operating costs which increased by € 47m to € 86.8m including growth of 1/ € 32.1m for R&D (€ 64.7m in H1 2024 vs € 32.6m in H1 2023) due mainly to progress on the clinical phase III programme for obefazimod in UC, 2/ € 4.2m for S&M expenses (€ 4.2m vs € 0.2m ) relating to the preparation of the launch of obef...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.